- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02632422
AIH-induced Walking Recovery After Subacute SCI
Intermittent Hypoxia-Induced Recovery of Overground Walking in Persons With Subacute SCI
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30309
- Shepherd Center
-
-
Massachusetts
-
Cambridge, Massachusetts, United States, 02138
- Spaulding Rehabilitation Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 to 70 years old
- medically stable with medical clearance from physician to participate
- spinal cord injury (SCI) at or below C3 (phrenic sparing) and above L5 with at least motor function preserved below the neurologic level
- non-progressive etiology of spinal injury
- American Spinal Injury Association Impairment Scale (AIS) grade A-D
- 2-12 months post-injury (subacute)
Exclusion Criteria:
- severe concurrent illness or pain, including unhealed decubiti, severe neuropathic or chronic pain syndrome, infection (e.g. bladder), hypertension, cardiovascular disease, pulmonary disease, severe osteoporosis (history of fractures), active heterotopic ossification in the lower extremities, or history of peripheral nerve injury in the legs
- score less than 24 on Mini-Mental Exam
- severe autonomic dysreflexia
- history of cardiovascular/pulmonary complications
- pregnancy
- severe obstructive sleep apnea (OSA), characterized by uncontrolled hypoxia and sleep fractionation
Specific inclusion/exclusion criteria for recruiting non-ambulatory subjects:
Participation in this group requires all of the above inclusion/exclusion criteria, as well as being unable to complete any of the below measures:
- timed up-and-go (TUG) test
- 10-meter walk test (10MWT)
- 6-minute walk test (6MWT)
Specific inclusion/exclusion criteria for recruiting ambulatory subjects:
Participation in this group requires all of the above criteria, as well as successful completion of at least one below measure:
- timed up-and-go (TUG) test
- 10-meter walk test (10MWT)
- 6-minute walk test (6MWT)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Non-ambulatory - dAIH
Non-ambulatory subjects will be randomly assigned to receive 10 sessions of daily acute intermittent hypoxia (dAIH) 10 treatment visits at a frequency of 5 days each week for 2 weeks.
|
Each participant will be exposed to 10 sessions of daily acute intermittent hypoxia (dAIH) via air generators.
The generator will fill reservoir bags attached to a non-rebreathing facemask.
Each session will consist of 15 episodes which include intervals of 1.5 minute hypoxia (FIO2=0.10±0.02,
i.e. 10% O2) and 1 minute normoxia (FIO2=0.21±0.02).
Participants will receive 5 consecutive days of daily acute intermittent hypoxia (dAIH).
|
Sham Comparator: Non-ambulatory - dSHAM
Non-ambulatory subjects will be randomly assigned to receive 10 sessions of daily room air (dSHAM) 10 treatment visits at a frequency of 5 days each week for 2 weeks.
|
Each participant will be exposed to 10 sessions of daily room air (dSHAM) via air generators.
The generator will fill reservoir bags attached to a non-rebreathing facemask.
Each session will consist of 15 episodes of 1.5 minute normoxia (FIO2=0.21±0.02).
Participants will receive 5 consecutive days of daily room air (dSHAM).
|
Experimental: Ambulatory - dAIH+Walk
Ambulatory subjects will be randomly assigned to receive 10 sessions of daily acute intermittent hypoxia (dAIH) coupled with 60 minutes of walking practice at a frequency of 5 days each week for 2 weeks.
|
Each participant will be exposed to 10 sessions of daily acute intermittent hypoxia (dAIH) via air generators.
The generator will fill reservoir bags attached to a non-rebreathing facemask.
Each session will consist of 15 episodes which include intervals of 1.5 minute hypoxia (FIO2=0.10±0.02,
i.e. 10% O2) and 1 minute normoxia (FIO2=0.21±0.02).
Participants will receive 5 consecutive days of daily acute intermittent hypoxia (dAIH).
Participants will participate in 10 days of walking practice sessions. Walking practice sessions will immediately follow (within 60 minutes) the breathing intervention during training visits and will last for 60 minutes. Walking practice will incorporate 5 walking-related tasks:
|
Sham Comparator: Ambulatory - dSHAM+Walk
Ambulatory subjects will be randomly assigned to receive 10 sessions of daily room air (dSHAM) coupled with 60 minutes of walking practice at a frequency of 5 days each week for 2 weeks.
|
Each participant will be exposed to 10 sessions of daily room air (dSHAM) via air generators.
The generator will fill reservoir bags attached to a non-rebreathing facemask.
Each session will consist of 15 episodes of 1.5 minute normoxia (FIO2=0.21±0.02).
Participants will receive 5 consecutive days of daily room air (dSHAM).
Participants will participate in 10 days of walking practice sessions. Walking practice sessions will immediately follow (within 60 minutes) the breathing intervention during training visits and will last for 60 minutes. Walking practice will incorporate 5 walking-related tasks:
|
Other: Ambulatory-Walk
Ambulatory subjects will be randomly assigned to 10 sessions of walking practice only for 5 consecutive sessions/week x 2 weeks.
|
Participants will participate in 10 days of walking practice sessions. Walking practice sessions will immediately follow (within 60 minutes) the breathing intervention during training visits and will last for 60 minutes. Walking practice will incorporate 5 walking-related tasks:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in walking recovery, assessed by timed up-and-go (TUG) test
Time Frame: Baseline, Post-session 10 (up to two weeks)
|
The TUG test is used to assess the dynamic balance of an individual.
It measures the amount of time (recorded in seconds) it takes for the individual to rise from a standard arm chair, walk a distance of 3 meters and return to the initial position resting against the back of the chair.
Participants will perform up to three trials of the TUG test.
Average speed across TUG trials will be used for analysis.
Change is the difference between the end of session 10 and baseline.
|
Baseline, Post-session 10 (up to two weeks)
|
Change in walking recovery, assessed by 6 minute walk test (6MWT)
Time Frame: Baseline, Post-session 10 (up to two weeks)
|
Participants perform the 6MWT at their fastest, most comfortable walking speed sustainable for 6 minutes.
Distances will be recorded at 2 and 6 minutes.
The test will be based upon the participant's ability to finish each assessment without human assistance.
Change is the difference between the end of session 10 and baseline.
|
Baseline, Post-session 10 (up to two weeks)
|
Change in walking recovery, assessed by 10 meter walk test (10MWT)
Time Frame: Baseline, Post-session 10 (up to two weeks)
|
Participants walk ten meters without assistance at their fastest, but safest speed with a minimum of 1-minute of rest between two trials.
Average speed across the up to three 10MWT trials will be used for analysis.
Change is the difference between the end of session 10 and baseline.
|
Baseline, Post-session 10 (up to two weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in pain severity
Time Frame: Baseline, Post-session 10 (up to two weeks)
|
Participants will report their pain level using the Wong-Baker FACES scale.
The scale is from 0 to 5; 0 being no pain and 5 being extreme pain.
Change is the difference between the end of session 10 and baseline.
|
Baseline, Post-session 10 (up to two weeks)
|
Change in spasticity
Time Frame: Baseline, Post-session 10 (up to two weeks)
|
Spasticity will be assessed using the Spinal Cord Assessment Tool for Spastic Reflexes (SCATS).
The study team will quantify the total lower extremity spasticity score using the cumulative sum of 3 SCATS subscales: clonus (0=no spasticity; 3=severe), flexor (0=no spasticity; 3=severe), and extensor (0=no spasticity; 3=severe).
Change is the difference between the end of session 10 and baseline.
|
Baseline, Post-session 10 (up to two weeks)
|
Systemic hypertension incidence rate
Time Frame: Post-session 10 (up to two weeks)
|
Participants will have their systolic and diastolic blood pressure measured.
A systemic hypertensive event is quantified as a systolic pressure exceeding 140mmHg and/or diastolic pressure exceeding 90mmHg.
A hypertension incident rate is the number of hypertensive events divided by the total person-time.
Person-time is in units of person-measures (the sum of the total number of BP measurements) taken for each person.
Person-measures accounts for the total number of chances for detecting a hypertensive event and accounts for measurements not made due to drop-out or a disqualifying adverse event
|
Post-session 10 (up to two weeks)
|
Autonomic dysreflexia incidence rate
Time Frame: Post-session 10 (up to two weeks)
|
The occurrence of autonomic dysreflexia will be assessed.
An autonomic dysreflexia event will constitute a participant having a systolic blood pressure (SBP) increase from baseline of 20mmHg or SBP greater than 150mmHg with complaints of headache, diaphoresis, and/or blurred vision and will be diagnosed by the study team clinicians.
|
Post-session 10 (up to two weeks)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Randy Trumbower, PT, PhD, Harvard Medical School (HMS and HSDM)
Publications and helpful links
General Publications
- Hayes HB, Jayaraman A, Herrmann M, Mitchell GS, Rymer WZ, Trumbower RD. Daily intermittent hypoxia enhances walking after chronic spinal cord injury: a randomized trial. Neurology. 2014 Jan 14;82(2):104-13. doi: 10.1212/01.WNL.0000437416.34298.43. Epub 2013 Nov 27.
- Trumbower RD, Jayaraman A, Mitchell GS, Rymer WZ. Exposure to acute intermittent hypoxia augments somatic motor function in humans with incomplete spinal cord injury. Neurorehabil Neural Repair. 2012 Feb;26(2):163-72. doi: 10.1177/1545968311412055. Epub 2011 Aug 5.
- Sohn WJ, Tan AQ, Hayes HB, Pochiraju S, Deffeyes J, Trumbower RD. Variability of Leg Kinematics during Overground Walking in Persons with Chronic Incomplete Spinal Cord Injury. J Neurotrauma. 2018 Nov 1;35(21):2519-2529. doi: 10.1089/neu.2017.5538. Epub 2018 Jun 5.
- Trumbower RD, Hayes HB, Mitchell GS, Wolf SL, Stahl VA. Effects of acute intermittent hypoxia on hand use after spinal cord trauma: A preliminary study. Neurology. 2017 Oct 31;89(18):1904-1907. doi: 10.1212/WNL.0000000000004596. Epub 2017 Sep 29.
- Peters DM, Thibaudier Y, Deffeyes JE, Baer GT, Hayes HB, Trumbower RD. Constraints on Stance-Phase Force Production during Overground Walking in Persons with Chronic Incomplete Spinal Cord Injury. J Neurotrauma. 2018 Feb 1;35(3):467-477. doi: 10.1089/neu.2017.5146. Epub 2017 Oct 27.
- Hayes HB, Chvatal SA, French MA, Ting LH, Trumbower RD. Neuromuscular constraints on muscle coordination during overground walking in persons with chronic incomplete spinal cord injury. Clin Neurophysiol. 2014 Oct;125(10):2024-35. doi: 10.1016/j.clinph.2014.02.001. Epub 2014 Feb 14.
- Naidu A, Peters DM, Tan AQ, Barth S, Crane A, Link A, Balakrishnan S, Hayes HB, Slocum C, Zafonte RD, Trumbower RD. Daily acute intermittent hypoxia to improve walking function in persons with subacute spinal cord injury: a randomized clinical trial study protocol. BMC Neurol. 2020 Jul 8;20(1):273. doi: 10.1186/s12883-020-01851-9.
- Tan AQ, Papadopoulos JM, Corsten AN, Trumbower RD. An automated pressure-swing absorption system to administer low oxygen therapy for persons with spinal cord injury. Exp Neurol. 2020 Nov;333:113408. doi: 10.1016/j.expneurol.2020.113408. Epub 2020 Jul 17.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017P001941
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Study Data/Documents
-
Informed Consent Form
Information comments: Requests for study informed consent may be made using the lab's contact form.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spinal Cord Injury
-
Taipei Veterans General Hospital, TaiwanThe Industrial Technology Research InstituteUnknownSpinal Cord Injuries | Complete Spinal Cord Injury | Incomplete Spinal Cord InjuryTaiwan
-
University of FloridaEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruitingSCI - Spinal Cord Injury | Incomplete Spinal Cord InjuryUnited States
-
Jill M. Wecht, Ed.D.Icahn School of Medicine at Mount SinaiRecruitingBlood Pressure | Spinal Cord Injuries | SCI - Spinal Cord Injury | Blood Pressure Disorders | Traumatic Spinal Cord Injury | Acute Spinal Cord Injury | Neuromodulation | Spinal Cord StimulationUnited States
-
NervGen PharmaRecruitingSpinal Cord Injuries | Chronic Spinal Cord Injury | Subacute Spinal Cord InjuryUnited States
-
MetroHealth Medical CenterNational Institute of Neurological Disorders and Stroke (NINDS); Case Western...RecruitingSpinal Cord Injuries | Spinal Cord Injury at C5-C7 Level | Spinal Cord Injury CervicalUnited States
-
Kevin KilgoreNational Institute of Neurological Disorders and Stroke (NINDS); Case Western... and other collaboratorsRecruitingSpinal Cord Injuries | Spinal Cord Injury at C5-C7 Level | Spinal Cord Injury Cervical | Spinal Cord Injury at C5-C7 Level With Complete Lesion | Spinal Cord Injury at C5-C7 Level With Incomplete LesionUnited States
-
The University of Texas Health Science Center,...TerminatedSpinal Cord Injuries | Cervical Spinal Cord Injury | Traumatic Spinal Cord CompressionUnited States
-
S.Biomedics Co., Ltd.Yonsei University; Linical Co., Ltd.RecruitingSpinal Cord Injury, Acute | Spinal Cord Injury at C5-C7 Level With Complete Lesion | Spinal Cord Injury at C4 Level With Complete LesionKorea, Republic of
-
StemCells, Inc.TerminatedStudy of Human Central Nervous System (CNS) Stem Cell Transplantation in Cervical Spinal Cord InjuryCervical Spinal Cord Injury | Spine Injury | Cervical Spine InjuryUnited States, Canada
-
Kessler FoundationNew Jersey Commission on Spinal Cord ResearchRecruitingSpinal Cord Injuries | Incomplete Spinal Cord InjuryUnited States
Clinical Trials on Daily acute intermittent hypoxia (dAIH)
-
University of Colorado, BoulderMedical University of South Carolina; University of Colorado, Denver; Eunice...Enrolling by invitationIncomplete Spinal Cord InjuryUnited States
-
Northwestern UniversityRecruitingHealthy Brain PerfusionUnited States
-
Shirley Ryan AbilityLabUnknownSpinal Cord InjuriesUnited States
-
Shirley Ryan AbilityLabEnrolling by invitation
-
Shirley Ryan AbilityLabEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingMultiple Sclerosis | Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis-Relapsing-RemittingUnited States
-
Shirley Ryan AbilityLabNational Multiple Sclerosis SocietyNot yet recruitingMultiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis, Secondary ProgressiveUnited States
-
University of FloridaCompletedNeuromuscular Diseases | Amyotrophic Lateral Sclerosis (ALS)United States
-
University of FloridaU.S. Army Medical Research Acquisition ActivityRecruiting
-
Shirley Ryan AbilityLabNational Institute of Neurological Disorders and Stroke (NINDS)Recruiting
-
Xinhua Hospital, Shanghai Jiao Tong University...Not yet recruiting